Why Veracyte Stock Is Back Under The Microscope Veracyte VCYT rattled investors after resetting near term expectations for its Decipher prostate cancer test, even as quarterly revenue growth remained solid and management
Veracyte, Inc. (VCYT) — Live Session & Technical Brief
Updated Nov 16, 2026 9:00 PM ET · Prev Close $24.33
Session Regime & Catalyst Assessment
64% Signal ConvictionControlled Session Consolidation (-1.32%) in Diagnostics & Research
Veracyte, Inc. (VCYT) is trading within a tight intraday band at $24.01 (-1.32%, 0.83x relative volume), signaling orderly institutional price discovery without an outlier shock. Relative to benchmarks, VCYT is outperforming the S&P 500 by +0.59%. 14-day RSI stands at 27.8, keeping momentum in a oversold regime.
Why Veracyte Stock Is Back Under The Microscope Veracyte VCYT rattled investors after resetting near term expectations for its Decipher prostate cancer test, even as quarterly revenue growth remained solid and management
Price ($24.01) trades relative to 20-day SMA ($39.20) and 50-day SMA ($41.79).
Market & Sector Relative Strength
VCYT outperforming the S&P 500 by +0.59%Recent VCYT Catalyst Headlines
Verified WireVeracyte NasdaqGM VCYT reported new predictive data on its Decipher Prostate Genomic Classifier in very high-risk nonmetastatic prostate cancer. The findings support using Decipher to identify patients who may benefit fr
VCYT beats Q3 earnings estimates but trims its 2026 revenue outlook as Decipher growth slows and investments in breast and bladder cancer testing rise.
Veracyte stock crashed almost 60 Thursday after the company reset growth expectations for its prostate cancer tissue test, Decipher.
1–3 Day Expected Range & Key Level
48% Follow-ThroughMonitor volume expansion above 1.5x RVOL around $23.27 (session support) for directional breakout confirmation.
Technical Regime (VCYT)
BEARISH MA TRENDRetail & Crowd Sentiment
BullishStockTwits messages suggest bullish sentiment on $VCYT, as one trader believes $VCYT will bottom when Apple (APLD) does. The trader also highlights the company's cash position of $370M and stock repurchase plan of $100M, implying a positive outlook.
About Veracyte, Inc.
Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder). In addition, its Percepta Nasal …
Get Instant VCYT Catalyst Alerts
Receive an email alert when VCYT triggers an unusual volume breakout, options sweep, or rating shift.
Other Liquid Stocks Moving Today
All Today's MoversVCYT Session & Catalyst FAQ
Why is VCYT stock trading near flat today?
Veracyte, Inc. (VCYT) is trading within a tight intraday band at $24.01 (-1.32%, 0.83x relative volume), signaling orderly institutional price discovery without an outlier shock. Relative to benchmarks, VCYT is outperforming the S&P 500 by +0.59%. 14-day RSI stands at 27.8, keeping momentum in a oversold regime.
Is VCYT stock a buy or sell right now?
Today's session carries a 64% catalyst conviction score on 0.83x relative volume (low participation). Our multi-factor model currently rates VCYT as HOLD. Review full valuation, quality, and timing signals on the VCYT Buy or Sell Decision Brief →
What is VCYT's intrinsic value and expected trading range?
At $24.01, VCYT's modeled 1-to-3 session range is $23.15 – $24.87, with a key inflection level at $23.27 (session support). Compare current price against multi-year cash flow projections in the VCYT Intrinsic Value & DCF Model → and Market Cycle Phase Tracker →
What do RSI and moving averages signal for VCYT?
RSI at 27.8 indicates oversold conditions — watch for mean-reversion support. VCYT trades at $24.01 relative to its 20-day SMA ($39.20) and 50-day SMA ($41.79), reflecting a bearish moving-average structure.
Tradestie Flagship Research & Market Hubs
Live institutional catalyst tape ranking liquid gainers, losers, options sweeps, and RVOL surges.
Track spot H100/B200 compute rental rates and frontier LLM inference token economics.
Wafer yield, CoWoS packaging, and HBM bill-of-materials teardown models across AI accelerators.
Monitor engineering velocity and upstream foundry wafer demand inflections across tech leaders.
Live conviction tracking, invalidation guardrails, and thesis health checks on flagship ideas.
Backtest-validated unusual options positioning and open-interest accumulation setups.
Daily ranked quantitative leaderboard with audited forward-return track record vs S&P 500.
High-yield, quality-screened cash-secured put and put-spread income candidates.